Enroll in Research > Research Search & Enroll Tool > The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations
The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

Surveys, Registries, Interviews

Study Contact Information:

To get involved or receive more information, please call or email us at:

T. 416-351-3765

E. narodstudy@wchospital.ca


The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

About the Study

Those who carry the BRCA1, BRCA2 or PALB2 gene mutations experience a higher lifetime risk of developing breast and ovarian cancer, but we need to know more about the other genetic and non-genetic factors that may also influence risk. This study follows women with these gene mutations over time, striving to build the evidence we need to help them and others make better decisions to protect their health.

In 1995, Dr. Steven Narod initiated the ‘Risk Factor Study’ which is currently the largest, long-term study among women with a mutation in the hereditary breast and ovarian cancer genes BRCA1 and BRCA2. With over 17,000 participants from around the world, our study seeks to improve our understanding of how hormonal, reproductive, and lifestyle factors may be associated with cancer in this high-risk population.

To get involved or receive more information, please call 416-351-3765 or email narodstudy@wchospital.ca the study team. 

Principal Investigator

Dr. Steven Narod is a globally recognized leader in the field of hereditary cancer and the most cited scientist in the field of breast cancer research. In fact, he contributed to the discovery of the BRCA1 gene in 1994.

This Study is Open To:
  • Women who have learned that they have a mutation in either the BRCA1, BRCA2 or PALB2 gene are eligible, regardless of their personal cancer history
  • Women who are 18 years of age or older
  • Participation is voluntary
This Study is Not Open To:
  • People who have not had genetic testing or who did not test positive for a BRCA1BRCA2 or PALB2 inherited mutation.